Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Masterflex SE (MZX.DE)
Gelsenkirchen, DE
Headquartered in Gelsenkirchen, Germany, Masterflex SE, established in 1987, is a global developer, manufacturer, and distributor of advanced hoses and connection systems tailored for diverse industrial and manufacturing environments. Under its flagship Masterflex brand, the company supplies a comprehensive range of high-performance hoses—including spiral, clip, film, monolayer, multilayer, co-extruded, and micro-extruded types—along with essential connecting components such as connectors, clamps, manifolds, distributors, drip chambers, and separating membranes. These solutions are vital for critical sectors like medical technology, life sciences, renewable energy, aviation, and both conventional and electric automotive industries. Furthermore, its Matzen & Timm brand focuses on specialized hoses, bellows, and custom molded parts, primarily serving the aerospace, automotive, and rail transport sectors. The Novoplast Schlauchtechnik division excels in the extrusion of various tubes and profiles, while Fleima-Plastic offers injection-molded parts and assembled plastic components for medical technology, cosmetics, and food processing applications. Lastly, the Masterduct brand delivers hoses specifically designed for heating, ventilation, and air conditioning (HVAC) systems.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.70% | +3.97% | +5.11% | +14.29% | +0.00% | +29.73% | +24.14% | +100.00% | +142.02% | -52.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+4.6% Q1'26: -0.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+5.8% Q1'26: +3.1% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+10.1% Q1'26: -1.5% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+13.5% ★ Q1'26: +16.4% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+13.5% ★ Q1'26: +17.6% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: +1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.78× ★ Q1'26: 0.62× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
53.00M
est: 51.50M (+2.9%)
|
54.98M
est: 57.23M (-3.9%)
|
57.90M
est: 59.01M (-1.9%)
|
62.47M
est: 62.67M (-0.3%)
|
64.11M
est: 64.05M (+0.1%)
|
66.49M
est: 66.67M (-0.3%)
|
74.68M
est: 74.40M (+0.4%)
|
77.24M
est: 77.85M (-0.8%)
|
79.97M
est: 80.00M (0.0%)
|
71.88M
est: 71.90M (0.0%)
|
79.07M
est: 78.40M (+0.9%)
|
100.27M
est: 98.87M (+1.4%)
|
101.12M
est: 100.37M (+0.7%)
|
98.07M
est: 98.73M (-0.7%)
|
102.58M
est: 102.59M (0.0%)
|
107.29M
106.69M – 107.89M
+4.6% YoY
|
118.09M
117.84M – 118.34M
+10.1% YoY
|
127.53M
126.90M – 128.17M
+8.0% YoY
|
135.98M
135.47M – 136.49M
+6.6% YoY
|
145.46M
144.91M – 146.01M
+7.0% YoY
|
| EBITDA |
11.11M
est: -1.66M (+769.0%)
|
10.02M
est: 6.73M (+48.8%)
|
8.67M
est: 6.52M (+33.1%)
|
9.12M
est: 9.26M (-1.5%)
|
7.74M
est: 7.09M (+9.2%)
|
8.60M
est: 5.51M (+56.1%)
|
9.78M
est: 6.10M (+60.4%)
|
9.45M
est: 7.73M (+22.1%)
|
9.17M
est: 7.58M (+20.8%)
|
7.32M
est: 6.43M (+13.8%)
|
10.26M
est: 6.89M (+48.9%)
|
16.45M
est: 6.79M (+142.3%)
|
17.66M
est: 25.48M (-30.7%)
|
18.00M
est: 25.06M (-28.2%)
|
19.43M
est: 26.04M (-25.4%)
|
27.24M
27.08M – 27.39M
+4.6% YoY
|
29.98M
29.92M – 30.04M
+10.1% YoY
|
32.38M
32.22M – 32.54M
+8.0% YoY
|
34.52M
34.39M – 34.65M
+6.6% YoY
|
36.93M
36.79M – 37.07M
+7.0% YoY
|
| EBIT |
8.65M
est: 6.56M (+31.8%)
|
7.40M
est: 8.33M (-11.2%)
|
6.06M
est: 7.84M (-22.7%)
|
6.35M
est: 5.70M (+11.2%)
|
4.97M
est: 6.65M (-25.3%)
|
5.91M
est: 4.99M (+18.4%)
|
6.61M
est: 6.79M (-2.6%)
|
6.10M
est: 7.43M (-17.9%)
|
4.57M
est: 6.23M (-26.7%)
|
2.35M
est: 4.39M (-46.6%)
|
5.35M
est: 4.70M (+13.7%)
|
11.40M
est: 4.64M (+146.0%)
|
12.37M
est: 20.52M (-39.7%)
|
12.55M
est: 20.19M (-37.8%)
|
13.88M
est: 20.98M (-33.9%)
|
21.94M
21.82M – 22.06M
+4.6% YoY
|
24.15M
24.10M – 24.20M
+10.1% YoY
|
26.08M
25.95M – 26.21M
+8.0% YoY
|
27.81M
27.70M – 27.91M
+6.6% YoY
|
29.74M
29.63M – 29.86M
+7.0% YoY
|
| Net Income |
4.14M
est: -2.36M (+275.7%)
|
4.44M
est: 4.33M (+2.5%)
|
2.88M
est: 4.54M (-36.4%)
|
3.04M
est: 4.98M (-38.9%)
|
1.95M
est: 3.20M (-39.2%)
|
2.93M
est: 2.00M (+46.6%)
|
4.31M
est: 3.26M (+32.2%)
|
3.37M
est: 4.53M (-25.5%)
|
2.53M
est: 3.45M (-26.5%)
|
793.0K
est: 2.45M (-67.6%)
|
3.28M
est: 2.62M (+25.2%)
|
7.78M
est: 7.38M (+5.4%)
|
7.99M
est: 8.57M (-6.7%)
|
8.23M
est: 8.07M (+2.0%)
|
8.71M
est: 8.87M (-1.7%)
|
9.84M
9.79M – 9.89M
+11.0% YoY
|
12.50M
11.90M – 13.26M
+27.0% YoY
|
14.20M
13.27M – 15.00M
+13.6% YoY
|
14.62M
14.55M – 14.69M
+3.0% YoY
|
15.87M
15.79M – 15.95M
+8.6% YoY
|
| SGA |
—
est: 820.0K (-100.0%)
|
6.34M
est: 555.6K (+1,041.1%)
|
6.29M
est: 2.06M (+204.8%)
|
6.67M
est: 6.32M (+5.5%)
|
7.74M
est: 9.43M (-17.9%)
|
6.94M
est: 10.47M (-33.7%)
|
7.68M
est: 10.65M (-27.9%)
|
8.63M
est: 10.90M (-20.8%)
|
8.64M
est: 11.77M (-26.6%)
|
7.34M
est: 10.59M (-30.8%)
|
8.28M
est: 11.34M (-27.0%)
|
10.27M
est: 11.18M (-8.1%)
|
10.14M
est: 11.58M (-12.4%)
|
10.29M
est: 11.39M (-9.6%)
|
16.86M
est: 11.83M (+42.4%)
|
12.38M
12.31M – 12.45M
+4.6% YoY
|
13.62M
13.59M – 13.65M
+10.1% YoY
|
14.71M
14.64M – 14.78M
+8.0% YoY
|
15.68M
15.63M – 15.74M
+6.6% YoY
|
16.78M
16.72M – 16.84M
+7.0% YoY
|
| EPS |
0.44
est: 0.44 (+0.1%)
|
0.50
est: 0.46 (+8.8%)
|
0.29
est: 0.38 (-24.4%)
|
0.34
est: 0.52 (-34.0%)
|
0.22
est: 0.30 (-26.7%)
|
0.34
est: 0.34 (+1.4%)
|
0.45
est: 0.42 (+5.9%)
|
0.35
est: 0.39 (-9.1%)
|
0.26
est: 0.25 (+4.0%)
|
0.08
est: 0.11 (-25.1%)
|
0.34
est: 0.35 (-2.5%)
|
0.81
est: 0.73 (+11.0%)
|
0.83
est: 0.89 (-7.2%)
|
0.86
est: 0.84 (+2.5%)
|
0.91
est: 0.92 (-1.3%)
|
1.02
1.02 – 1.03
+11.0% YoY
|
1.31
1.24 – 1.38
+27.8% YoY
|
1.47
1.38 – 1.56
+12.4% YoY
|
1.52
1.51 – 1.53
+3.4% YoY
|
1.65
1.64 – 1.66
+8.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andreas Bastin | Chairman of the Executive Board & Chief Executive Officer | 640.0K | — |
| Mark Becks | Chief Financial Officer & Member of the Executive Board | 457.0K | male |
| Christian Horstkoetter | Managing Director of Sales Europe -Industrial Solutions | — | — |
| Friedrich-Wilhelm Bischoping | Founder & Honorary Chairman of the Supervisory Board | — | male |
| Henrik Horndahl | MD of Scandinavia & Area Sales Manager Nordic Countries - Industrial Solutions | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MZX.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
